Title of article
Optimal haloperidol dosage for first episode schizophrenia
Author/Authors
J. Wong، نويسنده , , R. B. Zipursky، نويسنده , , M. Beiser، نويسنده , , G. Bean، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 1996
Pages
1
From page
513
To page
513
Abstract
There continues to be much uncertainty about what dosages of antipsychotic medication are optimal for the treatment of a first episode of schizophrenia. We investigated this question in a prospective controlled 4 week clinical trial involving a stepwise increase in haloperidol dosage. Patients were all suffering from a first episode of non-affective psychosis. “Optimal dosage” was established as that dosage at which there was either: a) clinical improvement defined as a minimum of 15% decrease on the total PANSS score, or b) the onset of extrapyramidal symptoms (EPS). Treatment began with haloperidol 2mg/day for 1 week and was increased on a weekly basis to 5mg/day, 10mg/day and 20 mg/day. If either criteria for “optimal dosage” was met after 1 week on any given dosage, then this dosage was continued for the remainder of the 4 week trial. Thirty-three of 36 patients entered into the study completed the full 4 week study (mean age=26.7 ± 5.8 yrs; 19 male, 14 female). Fourteen patients had an “optimal dosage” of 2 mg/day (14 responders, 0 EPS) while 9 patients were maintained on 5 mg/day (3 responders, 6 EPS), 7 patients on 10 mg/day (0 responders, 7 EPS) and 3 patients on 20 mg/day (2 responders, 1 EPS). The percent improvement on total PANSS at 4 weeks for those who were maintained on 2, 5, 10, and 20 mg was 74%, 47%, 25% and 33%, respectively. Twenty-five of 33 patients met criteria for clinical improvement at 4 weeks of whom 19 had plasma haloperidol levels which were less than 5 ng/ml. These findings suggest that patients being treated for a first episode of non-affective psychosis may respond to haloperidol dosages well below the commonly quoted therapeutic range. This is consistent with recent PET evidence confirming that high levels of D2 occupancy (>60%) are observed with dosages of haloperidol as low as 2mg/day. Support for this work was provided by the National Health Research and Development Program of Canada and the Ontario Mental Health Foundation.
Journal title
Biological Psychiatry
Serial Year
1996
Journal title
Biological Psychiatry
Record number
499755
Link To Document